Pearson T C, Darby C R, Bushell A R, West L J, Morris P J, Wood K J
Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, England.
Transplantation. 1993 Feb;55(2):361-7. doi: 10.1097/00007890-199302000-00025.
Transplantation tolerance can be induced in the adult mouse by the selective manipulation of the CD4+ T cell subset. C3H/He recipients with prolonged survival (> 120 days) of C57BL/10 cardiac allografts induced by treatment, at the time of transplantation, with the anti-CD4 mAb, YTS 191.1, were skin grafted simultaneously with donor-specific and third-party (BALB/c) skin. The development of donor-specific tolerance was proved by the specific prolongation of C57BL/10 skin graft survival, while third-party grafts were rejected. Further investigation of recipients with long-term surviving primary heart allografts showed that donor-specific tolerance was associated with organ-specific differences. Secondary cardiac allografts were universally accepted, even at 42 days after the primary heart transplant, while prolonged survival of donor-specific skin grafts was not obtained until more than 120 days after primary cardiac transplantation. Analysis of leukocyte reactivity in the mixed leukocyte culture (MLC) showed no correlation between the proliferative response of recipient T cells in vitro to either donor or third-party alloantigen and the survival of either heart of skin allografts. These results illustrate the significant challenge presented when attempting to define and assess accurately the state of transplantation tolerance.
通过对CD4 + T细胞亚群进行选择性操作,可在成年小鼠中诱导移植耐受。在移植时用抗CD4单克隆抗体YTS 191.1治疗,可使C57BL/10心脏同种异体移植在C3H/He受体中存活时间延长(>120天),这些受体同时接受供体特异性皮肤移植和第三方(BALB/c)皮肤移植。C57BL/10皮肤移植存活时间的特异性延长证明了供体特异性耐受的形成,而第三方移植则被排斥。对长期存活的原发性心脏同种异体移植受体的进一步研究表明,供体特异性耐受与器官特异性差异有关。二次心脏同种异体移植普遍被接受,即使在原发性心脏移植后42天也是如此,而供体特异性皮肤移植的存活时间延长直到原发性心脏移植后120多天才出现。混合淋巴细胞培养(MLC)中白细胞反应性分析表明,受体T细胞在体外对供体或第三方同种异体抗原的增殖反应与心脏或皮肤同种异体移植的存活之间没有相关性。这些结果说明了在试图准确界定和评估移植耐受状态时所面临的重大挑战。